Proves its acceptance as a first-line anti-microbial in pediatric LRTIs.
Expanded spectrum of activity & better tolerability
Effective in reducing symptoms of recurrent pharyngotonsillitis & prevents Recurrences
Higher cure rate than ceftrixone
In case of vulnerable bronchiopneumonia the percentage of overall success was 97.7% in the cefpodoxime proxetil group and 95.1% in the ceftriaxone group